MULTIPLE SCLEROSIS, RELAPSING-REMITTING

This study is observing how well the drug ofatumumab (brand name Kesimpta) works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday Italian clinics. It will follow 379 patients newly starting this treatment for 12 months to see its effects on relapses, disa…

This study looks at what happens when people with relapsing-remitting multiple sclerosis (MS) switch from the drug MabThera to a very similar, potentially cheaper version called Rixathon. Researchers are checking if the switch affects disease activity, safety, or disability progr…

This large, late-stage study is testing whether an investigational oral medication called IMU-838 can help control relapsing multiple sclerosis. It will compare the drug to a placebo in about 1,100 adults to see if it reduces relapses, slows disability progression, and is safe to…

This study is testing a medication called BIIB017 for teenagers (ages 10-17) with relapsing-remitting multiple sclerosis (MS). The main goals are to see if the drug is safe, well-tolerated, and effective at reducing MS relapses and brain lesions over two years. It also includes a…

This large trial aims to find the best treatment strategy for people newly diagnosed with relapsing-remitting multiple sclerosis (MS). It compares starting with powerful, higher-risk medications right away versus beginning with traditional, first-line therapies and only switching…

This study is testing if a combination of two treatments can improve muscle strength and nerve signals in people with multiple sclerosis (MS). The treatments are breathing brief, low levels of oxygen and using mild electrical stimulation on the leg. Researchers will measure ankle…

This study is testing whether following specific diets can improve quality of life for people with relapsing-remitting multiple sclerosis (MS). Researchers are comparing two special diets—a time-restricted olive oil ketogenic diet and a modified Paleolithic elimination diet—again…